NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT SEIZURE ACTIVITY
Fifth patent combined with a growing body of clinical data demonstrate safety and effectiveness of VALTOCO in this patient population, enhancing potential to expand clinical and commercial value. SAN DIEGO, CA — April 26, 2022 — Neurelis, Inc., a neuroscience-based company dedicated to enhancing therapeutic benefits and addressing significant unmet needs in managing central nervous system […]